(1) Somatropin has not been shown to increase the occurrence of scoliosis.

(2) Patients treated with somatropin should therefore have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or adjusted as needed.

(3) If papilledema is obsered by funduscopy during somatropin treatment, treatment should be discontinued.

(4) Somatropin is used to treat a number of conditions associated with a lack of growth hormone and short stature.

(5) Somatropin should not be used for growth promotion in pediatric patients with closed epiphysis or in patients with active proliferative or severe non- proliferative diabetic retinopathy.

(6) Symptoms usually occurred within the first eight weeks after initiation of somatropin therapy and generally resolve after cessation of therapy or a reduction of the somatropin dose.

(7) In patients with GHD, central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment.

(8) Norditropin should not be used in patients with known hypersensitivity to somatropin or any of its excipients.

(9) The study results suggest an increased risk of mortality with somatropin therapy compared to the general population.

(10) Blood glucose levels should be monitored periodically as treatment with somatropin may decrease insulin sensitivity.

(11) Any child having onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated.

(12) Funduscopic examination should be performed routinely before initiating and periodically during the course of somatropin therapy.

(13) Elderly patients may be more sensitive to the actions of somatropin and may be more prone to develop adverse reactions.

(14) The review will look into all available data on somatropin to reassess the benefit-risk balance of these medicines.

(15) Deaths have been reported in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment and are treated with somatropin.

(16) Doses of insulin or oral agents may need to be adjusted for patients with diabetes on somatropin therapy.

(17) Patients with preexisting diabetes or glucose intolerance should be monitored closely during somatropin therapy.